Monitor the shareholder vote results for the stock plan amendment, which could impact future equity dilution. The other proposals are routine and unlikely to affect operations.
Price Chart
Executive Summary
FATE THERAPEUTICS INC filed a definitive proxy statement for its 2026 annual shareholder meeting, proposing the election of three Class I directors, ratification of auditors, advisory approval of executive compensation, and an increase in shares available under its stock option plan.
Key Facts
- Annual shareholder meeting scheduled for June 12, 2026
- Proposing election of three Class I directors: Robert S. Epstein, Karin Jooss, and Laura J. Hamill
- Proposing to increase shares available under the 2022 Stock Option and Incentive Plan
- Proposing ratification of Ernst & Young LLP as independent auditors
- Proposing non-binding advisory approval of named executive officer compensation
Financial Impact
Potential dilution from increased shares in stock option plan, magnitude undisclosed
Risk Factors
- Increased share count from stock plan amendment could lead to shareholder dilution
- Shareholder opposition to executive compensation could signal governance concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-177171 |
| Document: 0001193125-26-177171-index-headers.html | 0001193125-26-177171 |
| Document: 0001193125-26-177171-index.html | 0001193125-26-177171 |
| Document: 0001193125-26-177171.txt | 0001193125-26-177171 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Press Release | $2.57 $2.34 | ▼ −8.95% | ▼ −6.96% | $2.31 (−10.31%) |
Aug 13, 2026 7w ago | 8-K | $2.52 $2.31 | ▼ −8.33% | ▼ −6.59% | $2.31 (−8.53%) |
Aug 5, 2026 8w ago | Insider Cluster | $2.49 $2.42 | ▲ +2.81% | ▲ +3.41% | $2.31 (+7.43%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.97 $3.11 | ▼ −57.87% | ▼ −55.98% | $2.31 (−17.01%) |
Jun 4, 2026 17w ago | 8-K | $1.98 $2.99 | ▲ +51.01% | ▲ +49.15% | $2.31 (+16.41%) |
Jun 1, 2026 17w ago | Press Release | $2.74 $2.70 | ▼ −1.46% | ▼ −0.16% | $2.31 (−15.88%) |
May 13, 2026 20w ago | 8-K | $2.14 $1.97 | ▼ −7.94% | ▼ −7.33% | $2.31 (+7.71%) |
May 11, 2026 20w ago | Press Release | $2.18 $1.90 | ▼ −12.84% | ▼ −12.54% | $2.31 (+5.73%) |
Apr 24, 2026 22w ago | DEFA14A | $1.31 $2.15 | ▲ +64.12% | ▲ +59.17% | $2.31 (+75.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access